Alvotech And Advanz Claim A Global First With Golimumab Filing

Simponi Biosimilar Application Accepted By EMA; Approval Anticipated In Q4 2025

 
• By Dave Wallace
  
Advanz and Alvotech are the first to file golimumab worldwide (Shutterstock)

More from Biosimilars

More from Generics Bulletin